Israeli deep-tech company NextSilicon has officially opened a new research and development center in Belgrade, Serbia.
The center is located in B23 Office Park, occupying approximately 1,200 m² on the 8th floor. It already employs more than 70 engineers and developers, with plans to hire about 50 more people by the end of 2026.
According to founder and CEO Elad Raz, the Serbian team is already having a significant impact on the company’s key technologies. “Serbia has exceeded expectations in terms of engineering talent and work culture,” he said.
The new center expands NextSilicon’s capabilities in high-performance computing (HPC) and artificial intelligence, including the development of the Maverick-2 product.
NextSilicon, founded in 2017, specializes in solutions for HPC and AI. Globally, the company has R&D centers and divisions in Israel, the US, Germany, Switzerland, and India. Its flagship product is the Maverick-2 chip, an Intelligent Compute Accelerator (ICA) focused on AI and HPC tasks. The company has a total of over 350 employees.
Farmak pharmaceutical company (Kyiv) is investing EUR 30 million in the construction of an innovative research R&D center in Kyiv.
According to a press release from the company, the center is to open in 2023.
According to Executive Director of Farmak Volodymyr Kostiuk, the decision to build an R&D center was made a few years ago due to the expansion of the geography of presence and the portfolio of medicines.
In the new center, in particular, analytical laboratories will be concentrated, they will have about a hundred liquid and gas chromatographs and a number of modern devices for the development and testing of drugs.
In addition, the R&D center will house a technological laboratory with equipment for the development of finished drugs with various methods of their delivery to the human body and the implementation of personalized medicine protocols of the 21st century.
In the new R&D center, it is planned to continue working in three main areas: finished dosage forms, proprietary active pharmaceutical ingredients, as well as an innovative area in which Farmak has been working since 2015 – biotechnological active pharmaceutical ingredients. All processes will be digitized.
In addition, on the basis of the new complex, a special location will be equipped for young scientists who are not employees of the company, where they can engage in scientific activities and create prototypes of drugs.
The concept design of the complex was developed by Makhno Studio.
Farmak is the leader of the Ukrainian pharmaceutical market. The company’s product portfolio includes about 200 brands. Among the main directions are endocrinological, gastroenterological, cardiological, neurological, anti-cold and other drugs.
Madgicx, an Ad-Tech platform, wants to hire 20 IT specialists over the next year in Ukraine.
As digital advertising, Madgicx focuses on condensing successful Facebook advertising techniques into an automated, artificial intelligence platform.
“We’ve heard good things about Ukraine,” Idan Beker, company CTO, says in Kyiv. “Mainly that the workforce here has exceptional analytical skills and that they are devoted workers. The fact that the wages here are much cheaper than in Israel made our decision to hire our R&D team here.”
